GLP-1S and GLP-3R sit at opposite ends of the incretin receptor spectrum. GLP-1S is a selective single-receptor GLP-1 agonist, while GLP-3R engages three receptors: GIP, GLP-1, and glucagon.
| Property | GLP-1S | GLP-3R |
|---|---|---|
| Category | GLP-1 receptor agonist (single agonist) | GIP/GLP-1/glucagon triple receptor agonist ("triple G") |
| Mechanism of Action | Selective GLP-1 receptor activation in receptor-expressing cell lines | Simultaneous GIP, GLP-1, and glucagon receptor activation |
| Molecular Weight | ~4,113 Da | ~4,731 Da |
| Research Focus | GLP-1 receptor-selective signaling assays | Three-receptor signaling and receptor cross-talk assays |
| Receptor Target | GLP-1 receptor (selective) | GIP receptor + GLP-1 receptor + glucagon receptor |
| Half-Life | ~7 days (C-18 fatty diacid, albumin binding) | ~6 days (fatty diacid modification, albumin binding) |
GLP-1S is the reference single-receptor GLP-1 agonist and is widely used as a selective control in incretin receptor assays. GLP-3R is a multi-receptor agonist that layers GIP and glucagon receptor activity on top of GLP-1 agonism. The comparison illustrates the move from selective single-receptor agonism toward multi-receptor engagement in peptide pharmacology.
GLP-1S is a selective GLP-1 receptor agonist. GLP-3R is a triple agonist targeting GIP, GLP-1, and glucagon receptors. The two are used together to compare single-receptor and three-receptor signaling in cell-based assays; GLP-3R has the smaller published dataset.
Disclaimer: All compounds referenced on this page are sold for research and laboratory use only. The comparisons presented are based on published scientific literature and are intended for educational and informational purposes. This content does not constitute medical advice. Researchers should consult primary literature and applicable regulations before designing study protocols.